Download PDF
Planta Med 2019; 85(05): 406-411
DOI: 10.1055/a-0818-3689
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Catalpol Ameliorates Neointimal Hyperplasia in Diabetic Rats

Chiu-Mei Lin
1   Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
2   Faculty of Medicine, School of Medicine, Fu Jen Catholic University, Taipei, Taiwan
3   Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taipei, Taiwan
,
Bao-Wei Wang
4   Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
,
Wei-Jen Fang
4   Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
,
Chun-Ming Pan
4   Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
,
Kou-Gi Shyu   *
5   Division of Cardiovascular diseases, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
,
Sheng-Wen Hou   *
1   Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
2   Faculty of Medicine, School of Medicine, Fu Jen Catholic University, Taipei, Taiwan
› Author Affiliations
Further Information

Publication History

received 02 August 2018
revised 22 November 2018

accepted 03 December 2018

Publication Date:
04 January 2019 (online)

    Permissions and Reprints

Abstract

Catalpol, an iridoid glycoside, is an isolated natural product of Rehmannia glutinosa, which has been reported to have antidiabetic properties. This study investigated the vascular protective effects of catalpol in hyperglycemic rats with balloon-injured carotid arteries. Balloon injury stress led to the upregulation of monocyte chemoattractant protein-1 expression in rats with streptozotocin-induced diabetes. Western blotting and real-time PCR were performed. In situ hybridization, immunohistochemistry, and confocal analyses were employed. Monocyte chemoattractant protein-1 levels were increased through streptozotocin induction or balloon injury. After treatment with catalpol, the neointimal hyperplasia area was reduced 2 weeks after balloon injury in hyperglycemic rats. Real-time PCR and immunohistochemical analysis demonstrated reduced levels of monocyte chemoattractant protein-1 2 weeks after the balloon injury. Monocyte chemoattractant protein-1 expression was significantly increased in balloon-injured rats compared with the control groups. Thus, treatment with catalpol affected monocyte chemoattractant protein-1 expression. This study demonstrated that catalpol downregulated monocyte chemoattractant protein-1 expression in carotid arteries and ameliorated neointimal hyperplasia in hyperglycemic rats. The suppressive effect of monocyte chemoattractant protein-1 suggests that it plays a key role in neointimal hyperplasia. The results imply that catalpol is potentially effective for preventing hyperglycemia-related ischemic cardiac diseases.

Key words

catalpol - iridoid glycoside - hyperglycemia - neointimal hyperplasia - balloon injury - MCP-1

* Kou-Gi Shyu and Sheng-Wen Hou contributed equally to this work.


Supporting Information

    Supplementary Fig. 1: Image of catalpol attenuated monocyte recruitment on monocyte adhesion assay with a concentration dependent manner (from 0.1 mM to 1 mM) in vascular smooth muscle cell cultures under high glucose condition. Supplementary Fig. 2: Panel A, effects of different concentration of streptozotocin on increasing blood glucose level. Panel B, effects of catalpol (5 mg/kg) on the level of blood glucose of experimental rats.

  • Supporting Information
 

  • References

  • 1 Dokken BB. The pathophysiology of cardiovascular disease and diabetes: Beyond blood pressure and lipids. Diabetes Spectr 2008; 21: 160-165
    CrossrefPubMedGoogle Scholar
  • 2 Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013; 2013: 653789
    PubMedGoogle Scholar
  • 3 Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen-Maycock CA, Bair TL, Pearson RR, Carlquist JF. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003; 146: 351-358
    CrossrefPubMedGoogle Scholar
  • 4 Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 6: 1246-1258
    CrossrefPubMedGoogle Scholar
  • 5 Wall VZ, Bornfeldt KE. Arterial smooth muscle. Arterioscler Thromb Vasc Biol 2014; 34: 2175-2179
    CrossrefPubMedGoogle Scholar
  • 6 Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des 2014; 20: 4580-4588
    CrossrefPubMedGoogle Scholar
  • 7 Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine 2012; 60: 1-12
    CrossrefPubMedGoogle Scholar
  • 8 Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamato K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadawaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602-26614
    CrossrefPubMedGoogle Scholar
  • 9 Si Y, Ren J, Wang P, Rateri DL, Daugherty A, Shi XD, Kent KC, Liu B. Protein kinase C-delta mediates adventitial cell migration through regulation of monocyte chemoattractant protein-1 expression in a rat angioplasty model. Arterioscler Thromb Vasc Biol 2012; 32: 943-954
    CrossrefPubMedGoogle Scholar
  • 10 Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103: 773-778
    CrossrefPubMedGoogle Scholar
  • 11 Zhu H, Wang Y, Liu Z, Wang J, Wan D, Feng S, Yang X, Wang T. Antidiabetic and antioxidant effects of catalpol extracted from Rehmannia glutinosa (Di Huang) on rat diabetes induced by streptozotocin and high-fat, high-sugar feed. Chin Med 2016; 11: 25
    CrossrefPubMedGoogle Scholar
  • 12 Zhang X, Zhang A, Jiang B, Bao Y, Wang J, An L. Further pharmacological evidence of the neuroprotective effect of catalpol from Rehmannia glutinosa . Phytomedicine 2008; 15: 484-490
    CrossrefPubMedGoogle Scholar
  • 13 Han Y, Shen M, Tang LY, Tan G, Yang QC, Ye LH, Jiang N, Gao GP, Shao Y. Antiangiogenic effects of catalpol on rat corneal neovascularization. Mol Med Rep 2018; 17: 2187-2194
    PubMedGoogle Scholar
  • 14 Park KS. Catalpol reduces the production of inflammatory mediators via PPAR-γ activation in human intestinal Caco-2 cells. J Nat Med 2016; 70: 620-626
    CrossrefPubMedGoogle Scholar
  • 15 Jia Y, Gong N, Li TF, Zhu B, Wang YX. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway. Pharmacol Res 2015; 102: 276-285
    CrossrefPubMedGoogle Scholar
  • 16 Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis 2010; 20: 474-480
    CrossrefPubMedGoogle Scholar
  • 17 Ku SK, Bae JS. Baicalin, baicalein and wogonin inhibits high glucose-induced vascular inflammation in vitro and in vivo . BMB Rep 2015; 48: 519-524
    CrossrefPubMedGoogle Scholar
  • 18 Shieh JP, Cheng KC, Chung HH, Kerh YF, Yeh CH, Cheng JT. Plasma glucose lowering mechanisms of catalpol, an active principle from roots of Rehmannia glutinosa, in streptozotocin-induced diabetic rats. J Agric Food Chem 2011; 59: 3747-3753
    CrossrefPubMedGoogle Scholar
  • 19 Zhang R, Zhou J, Li M, Ma H, Qiu J, Luo X, Jia Z. Ameliorating effect and potential mechanism of Rehmannia glutinosa oligosaccharides on the impaired glucose metabolism in chronic stress rats fed with high-fat diet. Phytomedicine 2014; 21: 607-614
    CrossrefPubMedGoogle Scholar
  • 20 Huang WJ, Niu HS, Lin MH, Cheng JT, Hsu FL. Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats. J Nat Prod 2010; 73: 1170-1172
    CrossrefPubMedGoogle Scholar
  • 21 Lu J, Ji J, Meng H, Wang D, Jiang B, Liu L, Randell E, Adeli K, Meng QH. The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovasc Diabetol 2013; 12: 58
    CrossrefPubMedGoogle Scholar
  • 22 Guo J, Pereira TJ, Dalvi P, Yeung LSN, Swain N, Breen DM, Lam L, Dolinsky VW, Giacca A. High-dose metformin (420 mg/kg daily p.o.) increased insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis. Metabolism 2017; 68: 108-118
    CrossrefPubMedGoogle Scholar
  • 23 Yan J, Wang C, Jin Y, Meng Q, Liu Q, Liu Z, Liu K, Sun H. Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway. Pharmacol Res 2018; 130: 466-480
    CrossrefPubMedGoogle Scholar
  • 24 Liu YJ, Zheng CZ, Hao ZP, Zhang DJ, Mao AW, Yuan P. Catalpol ameliorates diabetic atherosclerosis in diabetic rabbits. Am J Transl Res 2016; 8: 4278-4288
    PubMedGoogle Scholar
  • 25 Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119
    CrossrefPubMedGoogle Scholar
  • 26 Qi H, Jing Z, Xiaolin W, Changwu X, Xiaorong H, Jian Y, Jing C, Hong J. Histone demethylase JMJD2A inhibition attenuates neointimal hyperplasia in the carotid arteries of balloon-injured diabetic rats via transcriptional silencing: inflammatory gene expression in vascular smooth muscle cells. Cell Physiol Biochem 2015; 37: 719-734
    CrossrefPubMedGoogle Scholar
  • 27 Choi HJ, Jang HJ, Chung TW, Jeong SI, Cha J, Choi JY, Han CW, Jang YS, Joo M, Jeong HS, Ha KT. Catalpol suppresses advanced glycation end-products-induced inflammatory response through inhibition of reactive oxygen species in human monocytic THP-1 cells. Fitoterapia 2013; 86: 19-28
    CrossrefPubMedGoogle Scholar
  • 28 Liu JY, Zhang DJ. Amelioration by catalpol of atherosclerotic lesions in hypercholesterolemic rabbits. Planta Med 2015; 8: 175-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Koksal B. Effect of streptozotocin on plasma insulin levels of rats and mice: A meta-analysis study. Open Access Maced J Med Sci 2015; 3: 380-383
    CrossrefPubMedGoogle Scholar
  • 30 Shyu KG, Cheng WP, Wang BW. Angiotensin II downregulates microRNA-145 to regulate kruppel-like factor 4 and myocardin expression in human coronary arterial smooth muscle cells under high glucose conditions. Mol Med 2015; 21: 616-625
    CrossrefPubMedGoogle Scholar
  • 31 Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012; 7: e35007
    CrossrefPubMedGoogle Scholar
  • 32 Lin CM, Chang H, Chen YH, Wu IH, Chiu JH. Wogonin inhibits IL-6-induced angiogenesis via down-regulation of VEGF and VEGFR-1, not VEGFR-2. Planta Med 2006; 72: 1305-1310
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Lin CM, Wang BW, Pan CM, Fang WJ, Chua SK, Chang H, Shyu KG. Effects of flavonoids on MicroRNA 145 regulation through Klf4 and myocardin in neointimal formation in vitro and in vivo . J Nutr Biochem 2018; 52: 27-35
    CrossrefPubMedGoogle Scholar